There are currently 604 clinical trials in Richmond, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Virginia Commonwealth University, Virginia Commonwealth University/Massey Cancer Center, VCU Massey Comprehensive Cancer Center and Virginia Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: Virginia Commonwealth University Health System, Richmond, Virginia
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates
Lived Experiences of Black Girls in Richmond
NCT05858281
Recruiting
This study is to understand the quality of life of Black Girls in Richmond, Virginia, which includes generating a report about the status of Black girls in Richmond. Research or reports about the state of the girls are growing more common across the country in cities like Los Angeles, Chicago, and Philadelphia. Most of these studies generate deficit narratives focusing on these groups' problems, needs, and deficiencies. Fewer studies focus solely on the experience of Black girls specifically. Th... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/29/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Lived Experiences, Strengths, and Community Assets of Black Girls
Register for Updates
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
NCT06685692
Recruiting
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)
Gender:
ALL
Ages:
21 years and above
Trial Updated:
01/28/2025
Locations: Bon Secours Liver Institute of Newport News, Richmond, Virginia
Conditions: Alcohol Hepatitis
Register for Updates
Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs
NCT02493478
Recruiting
Advanced airway interventions are common high risk, high stakes events for children in intensive care units (ICU) and emergency departments (ED), with risk for life and health threatening consequences.
Gender:
ALL
Ages:
All
Trial Updated:
01/21/2025
Locations: Children's Hospital of Richmond at VCU, Richmond, Virginia
Conditions: Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Register for Updates
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT05309655
Recruiting
The purpose of this research study is to understand what effect near complete estrogen deprivation (NCED) therapy has on the heart in breast cancer patients. Investigators want to understand if NCED changes how the heart works.
Gender:
FEMALE
Ages:
Between 18 years and 55 years
Trial Updated:
01/21/2025
Locations: Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia
Conditions: Breast Cancer, Triple Negative Breast Cancer, Cardiovascular Complications
Register for Updates
Nonalcoholic Fatty Liver Disease in HIV Database
NCT05023044
Recruiting
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure. The spectrum of NAFLD encompasses simple nonalcoholic steatosis (nonalcoholic fatty liver \[NAFL\]) and nonalcoholic steatohepatitis (NASH) in which there is evidence of hepatocellular injury and/or fibrosis. NAFLD is the most common liver disease in adults and the second l... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv
Register for Updates
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention
NCT00733590
Recruiting
The overall hypothesis of this study is that subtle interactions between structural (substrate) and functional (trigger) abnormalities of the heart, some of which are genetically-determined, can be used to identify patients at high risk of sudden cardiac death (SCD). Such information may be used to better define patients most likely to benefit from replacement of an internal defibrillator (ICD). The prospective, observational study to enroll, categorize and follow patients who receive an ICD pul... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/10/2025
Locations: Virginia Commonwealth University School of Medicine, Richmond, Virginia
Conditions: Heart Failure, Congestive, Death, Sudden, Cardiac, Arrhythmia, Cardiomyopathies
Register for Updates
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
NCT04916327
Recruiting
The purpose of this research study is to examine the role oxidants, substances produced in the blood that can damage blood vessel function, may play in blood vessel function in healthy individuals as well as individuals with mental health disorders (posttraumatic stress disorder (PTSD) and/or generalized anxiety disorder (GAD)).
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
01/10/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Peripheral Vascular Diseases
Register for Updates
Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure
NCT05177822
Recruiting
Patients who have a heart attack are at high risk for future development of heart failure ('weakening of the heart'). The researchers believe that the reaction of the heart muscle to injury (inflammation) during a heart attack may be contributing to the risk of heart failure. The current study will test the ability of an anti-inflammatory medicine (anakinra) to block the inflammation in the body during and after a heart attack.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
01/10/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Heart Failure
Register for Updates
Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
NCT05685745
Recruiting
The goal of the Tiny Baby Collaborative Multicenter Inventory of Neonatal-Perinatal Interventions (MINI) minimum dataset is to serve as a registry detailing the outcomes and practices for all deliveries and infants admitted to intensive care at 22-23 weeks' gestation at participating hospitals.
Gender:
ALL
Ages:
Between 0 years and 1 year
Trial Updated:
01/10/2025
Locations: Children's Hospital of Richmond, Richmond, Virginia
Conditions: Infant, Extremely Premature, Obstetric Labor, Premature, Premature Birth, Intensive Care, Neonatal, Intensive Care Units, Neonatal
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Bon Secours Saint Mary's Hospital, Richmond, Virginia +4 locations
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
Neuroscience-informed Treatment to Remotely Target Reward Mechanisms in Post-acute Anorexia Nervosa
NCT05799872
Recruiting
The investigators will recruit individuals with broadly-defined AN (n = 80) who are currently in or have recently participated in higher-level eating disorder treatment (e.g., residential, partial hospitalization/day treatment, intensive outpatient treatment). Interested participants will sign consent, complete eligibility assessments, and will be randomized to receive Positive Affect Treatment for Anorexia Nervosa (PAT-AN) or Psychoeducation and Behavioral Therapy (PBT) through teletherapy shor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Anorexia Nervosa
Register for Updates